Immunitybio is trading at $9.31, up +5.44%, while the reason for the September 30 move remains unclear.
- No clear company-specific announcement explaining the move was identified in available news results; recent FDA filing coverage predates this session.
- The supplied market snapshot showed mixed major-index moves, none exceeding 0.5%, and does not establish a broad-market explanation.
- Earlier developments include the ANKTIVA supplemental FDA application and second-quarter revenue growth, neither confirmed as today’s catalyst. No verified trading-volume or activity-level figure was available in the supplied price context.